Medicare Enrolled
Dr. Ayman Barakat, M.D.
Medical Oncology · Spring Hill, FL
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Barakat from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Barakat? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Barakat
Dr. Ayman Barakat is a medical oncology in Spring Hill, FL, with 18 years in practice. Based on federal Medicare data, Dr. Barakat performed 167,489 Medicare services across 3,777 unique beneficiaries.
Between the years covered by Open Payments, Dr. Barakat received a total of $12,324 from 90 pharmaceutical and/or device companies across 687 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Barakat is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 18 years in practice▲ Top 15% volume in FL$ $12,324 industry payments
Medicare Practice Summary
Medicare Utilization ↗167,489
Medicare services
Top 15% in FL for medical oncology
3,777
Unique beneficiaries
$8
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~9,305 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) | 39,270 | $0 | $4 |
| Iron infusion (Injectafer) | 26,250 | $1 | $3 |
| Iron sucrose injection (Venofer) | 18,300 | $0 | $5 |
| Anti-nausea injection (aprepitant) | 14,560 | $1 | $5 |
| Pembrolizumab injection (Keytruda) | 12,400 | $43 | $137 |
| Oxaliplatin chemotherapy injection | 11,200 | $0 | $12 |
| Denosumab injection (Prolia/Xgeva) | 7,500 | $19 | $51 |
| Epoetin alfa injection (Procrit) for anemia | 7,480 | $6 | $23 |
| Filgrastim injection (Zarxio) for white blood cells | 6,720 | $0 | $2 |
| Immune globulin infusion (Gammagard) | 5,926 | $36 | $108 |
| Dexamethasone injection (steroid) | 2,407 | $0 | $3 |
| Complete blood count (CBC) with differential | 2,046 | $8 | $29 |
| Blood draw (venipuncture) | 1,941 | $8 | $9 |
| Anti-nausea injection (ondansetron/Zofran) | 1,256 | $0 | $9 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,240 | $1 | $28 |
| Iron infusion (Monoferric) | 1,200 | $16 | $57 |
| Office visit, established patient (30-39 min) | 1,174 | $95 | $339 |
| Injection, leucovorin calcium, per 50 mg | 1,132 | $3 | $12 |
| Drug injection, under skin or into muscle | 745 | $10 | $69 |
| Injection, fluorouracil, 500 mg | 682 | $2 | $7 |
| Injection of additional new drug or substance into vein | 456 | $12 | $61 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 373 | $47 | $189 |
| Administration of chemotherapy into vein, 1 hour or less | 372 | $97 | $378 |
| Office visit, established patient (20-29 min) | 335 | $68 | $239 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 322 | $22 | $84 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 235 | $1 | $6 |
| Injection, diphenhydramine hcl, up to 50 mg | 187 | $1 | $3 |
| Infusion into a vein for hydration, each additional hour | 179 | $10 | $42 |
| Infusion, normal saline solution , 1000 cc | 164 | $2 | $7 |
| Administration of chemotherapy into vein, each additional hour | 134 | $21 | $79 |
| Automated urinalysis | 123 | $2 | $8 |
| Injection, methylprednisolone sodium succinate, up to 40 mg | 118 | $3 | $11 |
| Red blood count, automated test | 107 | $4 | $10 |
| Infusion into a vein for hydration, 31-60 minutes | 106 | $24 | $156 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 106 | $15 | $56 |
| Injection of drug or substance into vein | 105 | $28 | $156 |
| Administration of additional new drug or substance into vein, 1 hour or less | 87 | $48 | $178 |
| Administration of additional new drug or substance into vein using push technique | 84 | $42 | $170 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 84 | $122 | $637 |
| Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | 55 | $17 | $59 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 53 | $137 | $562 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 49 | $1 | $7 |
| New patient office visit (45-59 min) | 46 | $112 | $453 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 43 | $15 | $56 |
| New patient office visit, complex (60-74 min) | 43 | $166 | $585 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 33 | $25 | $89 |
| Office visit, established patient, complex (40-54 min) | 29 | $132 | $474 |
| Initial hospital admission, high complexity | 21 | $137 | $556 |
| Initial hospital admission, moderate complexity | 11 | $103 | $377 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
44.2% high complexity
52.1% medium
3.7% routine
Industry Payment Transparency
Open Payments through 2024 ↗$12,324
Total received (2018-2024)
Avg $1,761/year across 7 years
Top 39% in FL for medical oncology
90
Companies
687
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$11,822 (95.9%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$502 (4.1%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$2,568
2023$2,186
2022$1,677
2021$1,111
2020$1,399
2019$1,690
2018$1,692
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$1,019
Celgene Corporation
$754
E.R. Squibb & Sons, L.L.C.
$722
AstraZeneca Pharmaceuticals LP
$633
Janssen Biotech, Inc.
$631
PFIZER INC.
$617
Genentech USA, Inc.
$612
Seagen Inc.
$473
Astellas Pharma US Inc
$407
Merck Sharp & Dohme LLC
$402
Amgen Inc.
$399
Gilead Sciences, Inc.
$399
GENZYME CORPORATION
$390
Lilly USA, LLC
$352
Merck Sharp & Dohme Corporation
$309
Eisai Inc.
$232
Bayer HealthCare Pharmaceuticals Inc.
$209
Incyte Corporation
$170
EMD Serono, Inc.
$167
Takeda Pharmaceuticals U.S.A., Inc.
$152
Daiichi Sankyo Inc.
$144
Bayer Healthcare Pharmaceuticals Inc.
$131
GlaxoSmithKline, LLC.
$114
AMAG Pharmaceuticals, Inc.
$112
Ipsen Biopharmaceuticals, Inc
$110
Boehringer Ingelheim Pharmaceuticals, Inc.
$109
Seattle Genetics, Inc.
$103
AbbVie Inc.
$100
Puma Biotechnology, Inc.
$100
SANOFI-AVENTIS U.S. LLC
$99
CSL Behring
$98
BeiGene USA, Inc.
$89
Octapharma USA, Inc.
$82
JAZZ PHARMACEUTICALS INC.
$77
Pharmacosmos Therapeutics Inc.
$74
TerSera Therapeutics LLC
$71
Kite Pharma, Inc.
$69
Janssen Pharmaceuticals, Inc
$68
GE HealthCare
$65
ARRAY BIOPHARMA INC
$57
AVEO Pharmaceuticals, Inc.
$55
TESARO, Inc.
$54
G1 Therapeutics, Inc.
$54
Alexion Pharmaceuticals, Inc.
$53
Karyopharm Therapeutics Inc.
$52
TAIHO ONCOLOGY, INC.
$51
Deciphera Pharmaceuticals Inc.
$50
Stemline Therapeutics Inc.
$50
Spectrum Pharmaceuticals Inc.
$49
MEDIVATION FIELD SOLUTIONS LLC
$45
Pharmacyclics LLC, an AbbVie Company
$42
SOBI, INC
$42
Kyowa Kirin, Inc.
$41
Regeneron Healthcare Solutions, Inc.
$39
Sumitomo Pharma America, Inc.
$37
Heron Therapeutics, Inc.
$37
Aveo Pharmaceuticals, Inc.
$35
Exelixis Inc.
$35
CTI BioPharma Corp.
$34
Epizyme, Inc.,
$32
Dendreon Pharmaceuticals LLC
$29
AbbVie, Inc.
$25
Mirati Therapeutics, Inc.
$24
Tempus AI, Inc
$23
ImmunoGen, Inc.
$22
Pharmacyclics LLC, An AbbVie Company
$22
Genmab U.S., Inc.
$21
PharmaEssentia USA Corporation
$20
EISAI INC.
$19
MorphoSys, US Inc.
$18
TG THERAPEUTICS, INC.
$18
Secura Bio, Inc.
$18
Dova Pharmaceuticals
$18
Acceleron Pharma, Inc.
$17
Agios Pharmaceuticals, Inc.
$17
ABBVIE INC.
$16
Lantheus Medical Imaging, Inc.
$16
Array BioPharma Inc.
$15
Taiho Oncology, Inc.
$15
Apellis Pharmaceuticals, Inc.
$15
Myovant Sciences Inc.
$15
PUMA BIOTECHNOLOGY, INC.
$15
R-Pharm US LLC
$14
Clovis Oncology, Inc.
$14
Sun Pharmaceutical Industries Inc.
$13
Global Blood Therapeutics, Inc.
$12
Foundation Medicine, Inc.
$12
EUSA Pharma (US) LLC
$12
Teva Pharmaceuticals USA, Inc.
$11
SECURA BIO, INC.
$8
Top 3 companies account for 20.3% of total payments
Associated products mentioned in payments ›
ADCETRIS · AFINITOR · ALUNBRIG · AUGTYRO · Afstyla · Alecensa · Aliqopa · Avastin · BENDEKA · BESREMI · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Bavencio · Braftovi · CABOMETYX · CALQUENCE · CEREZYME · CHANTIX · COPIKTRA · COSELA · CYRAMZA · Cinvanti · DARZALEX · Doptelet · ELIQUIS · ELITEK · ELREXFIO · EMEND · ENHERTU · ERBITUX · ERLEADA · EVENITY · Elahere · Empaveli · Enhertu · Epkinly · Erivedge · Erleada · FASLODEX · FERAHEME · FOTIVDA · FOUNDATIONONE · FRUZAQLA · Fabhalta · Farydak · Folotyn · GAUCHER-DISEASE · GAZYVA · GILOTRIF · Halaven · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · INFLECTRA · INJECTAFER · INLYTA · INREBIC · Ixempra · JADENU · JAKAFI · JEVTANA · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LONSURF · LORBRENA · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · Lonsurf · MEKINIST · MONJUVI · MONOFERRIC · NERLYNX · Nerlynx · Neulasta · Nexavar · Nplate · Nubeqa · OCTAGAM IMMUNE GLOBULIN (HUMAN) · ODOMZO · ONUREG · OPDIVO · OPDUALAG · ORGOVYX · OXBRYTA · Onivyde · Orserdu · PADCEV · PIQRAY · PLUVICTO · POTELIGEO · PROMACTA · PROVENGE · Padcev · Perjeta · Pomalyst · Poteligeo · Prolia · QINLOCK · Quadramet · REBLOZYL · RYBREVANT · Reblozyl · Revlimid · Rubraca · SARCLISA · SCEMBLIX · SOLIRIS · SOMATULINE DEPOT · SUTENT · Somatuline Depot · Stivarga · Sylvant · TABRECTA · TAGRISSO · TASIGNA · TAZVERIK · TECENTRIQ · TECVAYLI · TEVIMBRA · TIVDAK · TUKYSA · Trodelvy · UKONIQ · ULTOMIRIS · Ultomiris · VARUBI · VENCLEXTA · VERZENIO · VONJO · Venclexta · Vitrakvi · Vonjo · XALKORI · XARELTO · XGEVA · XPOVIO · XT CDX · XTANDI · Xofigo · Xtandi · Yescarta · ZEJULA · ZEPZELCA · ZOLADEX · Zevalin
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (96%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $7 per 100 Medicare services performed
Geographic Context
Medical Oncologys within 10 mi
9
Per 100K population
4.5
County median income
$63,193
Nearest hospital
SPRINGBROOK HOSPITAL
2.7 mi
2.7 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Barakat is a mixed practice specialist, with above-average Medicare volume (top 15% in FL), and low-engagement industry engagement, with 18 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Barakat experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Barakat performed 39,270 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Barakat receive payments from pharmaceutical companies?
Yes. Dr. Barakat received a total of $12,324 from 90 companies across 687 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Barakat's costs compare to other medical oncologys in Spring Hill?
Dr. Barakat's average Medicare payment per service is $8. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Barakat) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologys in Spring Hill
Browse medical oncologys in Spring Hill ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologys in FL
Medical Oncologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologys in FL
Which FL medical oncologys receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
Celgene Corporation Payments to Doctors
See all physicians who received payments from Celgene Corporation.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology